CSL (CSLLY) Total Long-Term Assets: $26,053 Mil (As of Dec. 2025)


CSLLY CSL Ltd CSLLY
73 GF Score
Price $20.68
GF Value $51.03
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL Total Long-Term Assets?

CSL CSLLY +3.09% 73 Total Long-Term Assets is $26,053 Mil as of Dec. 2025. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $51.03 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. CSL's Total Long-Term Assets for the quarter that ended in Dec. 2025 was $26,053 Mil.

CSL Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for CSL's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL Total Long-Term Assets Chart

CSL Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,767.20 11,885.30 26,975.00 27,254.00 27,554.00

CSL Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Jun25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26,975.00 27,158.00 27,254.00 27,554.00 26,053.00
CSLLY
73GF Score
CSL Ltd CSLLY
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSL Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $26,053 Mil mean?
CSL (CSLLY) has a Total Long-Term Assets of $26,053 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on CSL and its competitors.
Is CSL's Total Long-Term Assets too high?
CSL's current Total Long-Term Assets is $26,053 Mil. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Total Long-Term Assets compare to VRTX and REGN?
CSL's Total Long-Term Assets of $26,053 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on CSL and its competitors. CSL's current Total Long-Term Assets is $26,053 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $51.03, compared to a current price of $20.68 — trading 59.5% below its estimated fair value. The current Total Long-Term Assets is $26,053 Mil. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For CSL (CSLLY), the current Total Long-Term Assets is $26,053 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (CSLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of $20.68 is trading 59.5% below its estimated GF Value™ of $51.03. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for CSLLY:

  • Total Long-Term Assets: $26,053 Mil
  • GF Value™: $51.03 vs. price of $20.68 (59.5% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score

Get the complete analysis for CSLLY

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.68
Price
$51.03
GF Value